Overseas manufacturing, the low price of generics and other factors lead to a shortage of important drugs for cancer and ...
Here is what you need to know about drug shortages and how they affect care. In May, drug manufacturer Teva said it will ...
Editor’s Comment, Nelda Murri, PharmD: The public health consequences of national drug shortages are sobering ... following the announcement of a new drug shortage. One author has estimated ...
As drug shortages reach record levels, thousands of patients are facing delays in receiving treatments for cancer and other ...
HOW MANY DRUG SHORTAGES ARE THERE? There were 301 active national ... to a recent report written by Sen. Gary Peters, D-Mich., chairman of the Senate Committee on Homeland Security and ...
Widespread shortages of cancer drugs are forcing doctors to make difficult decisions about how to treat their patients, ...
There were 301 active national drug shortages through ... to a recent report written by Sen. Gary Peters, D-Mich., chairman of the Senate Committee on Homeland Security and Governmental Affairs.
Through the first three months of the quarter, there were 301 active national drug shortages ... report written by Sen. Gary Peters, D-Mich., chairman of the Senate Committee on Homeland Security ...
including nearly 50 new shortages that accumulated in the first three months of the year. The last time active drug shortages – including both newly reported and ongoing – were this high was ...
A recent report from the U.S. Senate Committee on Homeland Security and Governmental Affairs identified 295 active drug shortages ... suppliers could pose a national security risk.
Objective: To ascertain preventable and non-preventable risk factors for adverse drug events (ADEs) in elderly inpatients at hospital admission. Patients and Methods: This was a prospective study ...
The drug is used to treat inflammatory conditions like arthritis and psoriasis, along with certain types of cancer. Shortages of chemotherapy drugs are not a new phenomenon. A survey of 214 ...
